RKLY ROCKLEY PHOTONICS HLDGS LTD

Rockley Photonics’ CEO Andrew Rickman to Speak at the Commonwealth Trade and Investment Summit 2022

Rockley Photonics Holdings Limited (NYSE: RKLY), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced that Dr. Andrew Rickman, OBE, will join heads of government, senior ministers, and business leaders from across the Commonwealth to participate in the Commonwealth Trade and Investment Summit 2022.

Dr. Rickman, chairman and CEO of Rockley Photonics, will participate in a panel entitled Global Pandemic Preparedness. He will join fellow session participants Dr. Tedros Adhanom Ghebreyesus, director-general, World Health Organisation, via pre-recorded video; Sir Patrick Vallance, chief scientific adviser, UK Government; and Fergus Drake, CEO, Crown Agents. Lanre Akinola, head of content, Norwegian-African Business Association, will moderate the panel discussion.

The session will focus on the devastating impact of the Covid-19 pandemic on the health and livelihoods of Commonwealth citizens and the rest of the world alike and consider opportunities for a global approach and enhanced cooperation in the future. Topics will include technologies that emerged during the pandemic and the opportunity to increase equitability and access to quality healthcare as well as ways to strengthen health care systems and build better, stronger and more adaptive supply chains across the Commonwealth.

The Company plans to provide access to a live webcast of the session from the investor relations page of the Rockley Photonics Holdings Limited website at . A replay of the session is expected to be available following the Summit.

About Rockley Photonics

Formed in 2013, Rockley is a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions that target a portfolio of biomarkers. Rockley's ground-breaking end-to-end biosensing platform unlocks unique spectra-based biomarkers enabling insights into personal health and well-being. With next-generation biosensing platforms specifically designed for mobile health monitoring, Rockley is laying the foundation for a new generation of biomedical applications across multiple industries.

To learn more about Rockley, visit

EN
05/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ROCKLEY PHOTONICS HLDGS LTD

 PRESS RELEASE

Rockley Photonics Receives 2020 UK R&D Tax Credit and Files 2021 R&D T...

OXFORD, England & PASADENA, Calif.--(BUSINESS WIRE)-- Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced that it received 12.9 million pounds sterling ($15.5 million) for its fiscal 2020 R&D tax credit from HMRC, the tax agency of the UK government. The Company filed its fiscal 2021 R&D tax credit application and expects to file its fiscal 2022 R&D tax credit application in 2023. About Rockley Photonics Formed in...

 PRESS RELEASE

Rockley Photonics Announces Receipt of Notice from NYSE of Non-Complia...

OXFORD, England, & PASADENA, Calif.--(BUSINESS WIRE)-- Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced that it received a notice from the New York Stock Exchange (“NYSE”) on December 9, 2022, indicating that the Company is not in compliance with NYSE’s continued listing standards, which require an average market capitalization of not less than $50 million over a 30 trading-day period and stockholders’ equity of ...

 PRESS RELEASE

Rockley Photonics Announces Promotion of Richard A. (Randy) Meier to C...

OXFORD, England & PASADENA, Calif.--(BUSINESS WIRE)-- Rockley Photonics Holdings Limited (NYSE: RKLY), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced changes to its senior management team. These changes are intended to position the Company for its next phase of growth. Effective immediately, Richard A. Meier has been appointed president and chief executive officer, and will join the board of directors. Dr. Andrew Rickman has resigned as chief executive officer and will ...

 PRESS RELEASE

Rockley Photonics’ CEO Andrew Rickman to Speak at the Commonwealth Tra...

OXFORD, England & PASADENA, Calif.--(BUSINESS WIRE)-- Rockley Photonics Holdings Limited (NYSE: RKLY), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced that Dr. Andrew Rickman, OBE, will join heads of government, senior ministers, and business leaders from across the Commonwealth to participate in the Commonwealth Trade and Investment Summit 2022. Dr. Rickman, chairman and CEO of Rockley Photonics, will participate in a panel entitled Global Pandemic Preparedness. He will...

 PRESS RELEASE

Rockley Photonics Demonstrates Compact 4-Kelvin Silicon Photonics Modu...

OXFORD, England & PASADENA, Calif.--(BUSINESS WIRE)-- Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a global medical technology company focused on delivering leading edge silicon photonics-based biosensing solutions by targeting a portfolio of biomarkers, today announced a groundbreaking 4-Kelvin performance demonstration with its monolithic silicon photonics electro-absorption modulator technology that is key to the development of next-generation cryogenic interconnect technology. This advancement is intended to enable ultra-sensitive image detection and sensing devices to view...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch